Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Ghsr Dna Hypermethylation Is a New Epigenetic Biomarker for Gastric Adenocarcinoma and Beyond Publisher Pubmed



Amini M1 ; Foroughi K1 ; Talebi F1 ; Aghagolzade Haji H2 ; Kamali F3 ; Jandaghi P4, 5 ; Hoheisel JD6 ; Manoochehri M1, 7
Authors
Show Affiliations
Authors Affiliations
  1. 1. School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran
  2. 2. Department of Biochemistry, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran
  3. 3. Iran National Tumor Bank, Cancer Institute of Iran, Tehran, Iran
  4. 4. Department of Human Genetics, McGill University, Montreal, QC, Canada
  5. 5. McGill University and Genome Quebec Innovation Centre, Montreal, QC, Canada
  6. 6. Division of Functional Genome Analysis (B070), German Cancer Research Center (DKFZ), Heidelberg, Germany
  7. 7. Molecular Genetics of Breast Cancer (B072), German Cancer Research Center (DKFZ), Heidelberg, Germany

Source: Journal of Cellular Physiology Published:2019


Abstract

Aberrations of DNA methylation are early events in the development of tumors. In this study, we investigated the DNA methylation status of growth hormone secretagogue receptor (GHSR), a promising pan-cancer biomarker, in gastric cancer (GC). Initially, data sets from DNA methylation and gene expression studies available at Gene Expression Omnibus (GEO) were analyzed. Confirmation was done on primary tumor specimens and adjacent normal stomach tissue samples. Both analyses showed significant hypermethylation of GHSR. For further validation, The Cancer Genome Atlas data on stomach cancer was used. A receiver operating characteristic curve analysis yielded an area under the curve value of 0.85, corroborating its usefulness as a diagnostic marker. A genome-wide comethylation analysis revealed several correlated genes. CREB1 was found to act as an upstream regulator of this gene network. Furthermore, GHSR methylation was found to be a biomarker in several other tumor entities, namely cancers of the bladder, endometrium, esophagus, head and neck, liver, thyroid, kidney, and ovary. Our findings along with previous reports on other types of cancer suggest a high potential of GHSR gene methylation as a pan-cancer biomarker, which could be considered for liquid biopsy applications. © 2019 Wiley Periodicals, Inc.
Other Related Docs
16. Targeting Epigenetics in Cancer: Therapeutic Potential of Flavonoids, Critical Reviews in Food Science and Nutrition (2021)
20. Immunotherapy of Gastric and Esophageal Cancers, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)